Literature DB >> 32293782

Metabolic reprogramming in childhood acute lymphoblastic leukemia.

Yordan Sbirkov1,2, Hasan Burnusuzov2,3, Victoria Sarafian1,2.   

Abstract

The first observations of altered metabolism in malignant cells were made nearly 100 years ago and therapeutic strategies targeting cell metabolism have been in clinical use for several decades.  In this review, we summarize our current understanding of cell metabolism dysregulation in childhood acute lymphoblastic leukemia (cALL). Reprogramming of cellular bioenergetic processes can be expected in the three distinct stages of cALL: at diagnosis, during standard chemotherapy, and in cases of relapse. Upregulation of glycolysis, dependency on anaplerotic energy sources, and activation of the electron transport chain have all been observed in cALL. While the current treatment strategies are tackling some of these aberrations, cALL cells are likely to be able to rewire their metabolism in order to escape therapy, which may contribute to a refractory disease and relapse. Finally, here we focus on novel therapeutic approaches emerging from our evolving understanding of the alterations of different metabolic networks in lymphoblasts.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  Bioenergetics; cALL; cell metabolism; therapy

Year:  2020        PMID: 32293782     DOI: 10.1002/pbc.28255

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  2 in total

1.  The Protozoan Inhibitor Atovaquone Affects Mitochondrial Respiration and Shows In Vitro Efficacy Against Glucocorticoid-Resistant Cells in Childhood B-Cell Acute Lymphoblastic Leukaemia.

Authors:  Yordan Sbirkov; Tsvetomira Ivanova; Hasan Burnusuzov; Kalina Gercheva; Kevin Petrie; Tino Schenk; Victoria Sarafian
Journal:  Front Oncol       Date:  2021-03-15       Impact factor: 6.244

Review 2.  Insights on the Interplay between Cells Metabolism and Signaling: A Therapeutic Perspective in Pediatric Acute Leukemias.

Authors:  Laura Anselmi; Salvatore Nicola Bertuccio; Annalisa Lonetti; Arcangelo Prete; Riccardo Masetti; Andrea Pession
Journal:  Int J Mol Sci       Date:  2020-08-28       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.